COVID-19 rebound after oral treatment in a nursing home facility: A case series
Paxlovid (nirmatrevir/ritonavir) is a 2 drug regimen taken together twice daily for 5 days was authorized for emergency use for nonhospitalized patients who are at risk for the progression of coronavirus disease (COVID-19). However, recurrence of symptoms 2–8 days after completing the treatment cour...
Main Authors: | Alex P. Betrosian, Stavros M. Christou, Stavroula Kalathaki |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-12-01
|
Series: | Infectious Medicine |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2772431X22000521 |
Similar Items
-
Guía práctica de las nuevas alternativas terapéuticas frente a SARS-CoV-2 en pacientes con inmunomoduladores de uso frecuente en dermatología
by: M. Viedma-Martínez, et al.
Published: (2023-01-01) -
[Translated article] Practical Guide to New Treatments for SARS-CoV-2 Infection in Dermatology Patients Being Treated With Common Immunomodulators
by: M. Viedma-Martínez, et al.
Published: (2023-01-01) -
Hope and fear; Paxlovid for COVID-19 treatment: A Letter to the Editor
by: Alireza Pouramini, et al.
Published: (2022-07-01) -
A Community Pharmacist’s Guide to Oral COVID-19 Antivirals
by: Tyler C. Melton, et al.
Published: (2022-10-01) -
The effectiveness of Paxlovid treatment in long-term care facilities in South Korea during the outbreak of the Omicron variant of SARS-CoV-2
by: Hanul Park, et al.
Published: (2022-12-01)